The board of ERIS Lifesciences at its meeting held on 24 November 2025 has approved the acquisition of balance 30% of the total share capital of Swiss Parenterals, a subsidiary of the Company. Further, the board has approved the issuance of up to 23,06,372 equity shares of the Company on preferential basis to discharge the consideration for acquisition of 30% stake in Swiss Parenterals. Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 24 November 2025.Powered by Capital Market - Live News

Net profit of ERIS Lifesciences rose 31.23% to Rs 120.19 crore in the quarter ended September 2025 as against Rs 91.59 crore during the previous quarter ended September 2024. Sales rose 6.93% to Rs 790.15 crore in the quarter ended September 2025 as against Rs 738.95 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales790.15738.95 7 OPM %36.4835.80 - PBDT241.75209.59 15 PBT172.67129.11 34 NP120.1991.59 31 Powered by Capital Market - Live News

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live News

Eris Lifesciences has allotted 6,761 equity shares under ESOP on 30 August 2025. The paid-up share capital of the Company accordingly stands increased from Rs. 13,62,06,793/- (13,62,06,793 equity shares of Re. 1/- each) to Rs. 13,62,13,554/- (13,62,13,554 equity shares of Re. 1/- each).Powered by Capital Market - Live News